Prime Medicine (PRME) has released fresh FY 2025 figures, with Q3 results showing total revenue of US$1.2 million and a basic EPS loss of US$0.32, as net income excluding extra items recorded a loss of US$50.6 million. The company’s quarterly revenue has moved from US$0.2 million in Q3 2024 to US$2.2 million in Q4 2024, then to US$1.5 million in Q1 2025, US$1.1 million in Q2 2025, and US$1.2 million in Q3 2025. Over the same period, basic EPS ranged between losses of US$0.32 and US$0.46 per share. With trailing twelve month losses remaining substantial and no rewards highlighted in the recent risk and reward summary, investors may concentrate more on how Prime Medicine’s cash burn and margins compare with its development timetable rather than on near-term headline growth.

See our full analysis for Prime Medicine.

With the latest results now available, the next step is to compare these numbers with the most widely discussed narratives around Prime Medicine, assessing which views the data supports and which may warrant reconsideration.

US$197 million trailing losses frame the story

• On a trailing twelve month basis to Q3 2025, Prime Medicine reported total revenue of US$6.0 million and a net loss of about US$197.3 million, with basic EPS at a loss of US$1.44.
• Bears often focus on the pattern of widening losses, and the data backs that concern, as net loss over the last five years has grown at about 17.1% per year while forecasts also point to average earnings declines of around 3.8% per year.
  • That trailing loss of roughly US$197.3 million aligns with the view that the business is still in a heavy spend phase rather than moving toward break even.
  • Forecast revenue declines of about 52.4% per year over the next three years sit alongside these losses and reinforce the cautious, bearish angle on earnings quality.

Quarterly losses remain around US$50 million

• Across the last four reported quarters, quarterly net loss excluding extra items ranged from about US$42.3 million to US$55.3 million, including US$50.6 million in Q3 2025 and US$52.6 million in Q2 2025.
• What stands out for a more cautious view is that, even as quarterly revenue moved between US$0 and US$2.2 million over the last six reported quarters, the net loss stayed consistently in a band of roughly US$42 million to US$55 million. This fits the risk summary that highlights ongoing unprofitability with no projected move into profit within the next three years.
  • For example, Q4 2024 produced US$2.2 million in revenue but still came with a loss of about US$42.3 million, underlining that modest revenue shifts did not materially change the loss profile.
  • In Q2 2024, revenue was recorded at US$0 while the loss excluding extra items was around US$55.3 million, showing how expenses and investment levels are the main driver of results at this stage.

On this backdrop of steady quarterly losses, some investors who lean cautious may want a closer look at how bearish arguments line up against the underlying figures. 🐻 Prime Medicine Bear Case

P/B of 4.6x with no flagged rewards

• Prime Medicine is trading at a P/B of 4.6x, compared with a 2.7x average for the US biotech industry and a 4.5x peer average. The latest US$4.23 share price has come alongside substantial shareholder dilution and no specific rewards flagged in the recent risk summary.
• Critics highlight this P/B premium as tough to reconcile with the fundamentals, since the trailing twelve month net loss of about US$197.3 million and forecasts for revenue and earnings to decline over the next three years point to a business still relying heavily on capital rather than on growing cash inflows.
  • The fact that no rewards items were identified in the supplied risk and rewards data, while major risks include expected revenue declines of about 52.4% per year, adds weight to the cautious interpretation of that 4.6x P/B multiple.
  • Substantial shareholder dilution over the past year, combined with recent share price volatility versus the broader US market, further supports the view that investors are paying a relatively high multiple despite a loss profile and dilution history.

If you want to see how other investors connect these valuation signals and losses into a fuller story, the community narratives are a helpful next stop. 📊 Read the what the Community is saying about Prime Medicine.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Prime Medicine's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

If this all sounds cautious, that is the point. However, you do not have to accept it at face value. Check the numbers and see how they stack up against the 4 important warning signs.

See What Else Is Out There

Prime Medicine is still posting sizeable quarterly losses of roughly US$42 million to US$55 million on modest revenue, with no near term path to profit identified.

If you are uneasy with that loss profile and would rather focus on financially sturdier ideas, take a serious look at our 75 resilient stocks with low risk scores to find companies where risk scores and fundamentals might better match your comfort level.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.